Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Exelixis Inc
(NQ:
EXEL
)
28.90
-0.16 (-0.55%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Exelixis Inc
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Exelixis Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
February 17, 2022
From
Exelixis, Inc.
Via
Business Wire
Earnings Scheduled For February 17, 2022
February 17, 2022
Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.
Via
Benzinga
Earnings Preview For Exelixis
February 16, 2022
Exelixis (NASDAQ:EXEL) is set to give its latest quarterly earnings report on Thursday, 2022-02-17. Here's what investors need to know before the announcement. Analysts estimate that Exelixis will...
Via
Benzinga
Bristol Myers, Exelixis Tout Additional Opdivo/Cabometyx Combo Data From Kidney Cancer Trial
February 15, 2022
Bristol Myers Squibb Co (NYSE: BMY) and Exelixis Inc (NASDAQ: EXEL) announced two-year follow-up results from the Phase 3 CheckMate -9ER trial of Opdivo (...
Via
Benzinga
Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Continued Survival Benefits with Over Two Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
February 14, 2022
From
Bristol Myers Squibb
Via
Business Wire
The Sunday File for Nov. 21
November 21, 2021
Good news and bad - making up for the short week by getting a Sunday start.
Via
Talk Markets
Exelixis to Release Fourth Quarter and Full Year 2021 Financial Results on Thursday, February 17, 2022
February 03, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Webcast Virtual Fireside Chat as Part of the Guggenheim Healthcare Talks Oncology Day on February 9, 2022
February 02, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Detailed Results for Cabozantinib in Combination with Immunotherapies in Patients with Advanced Colorectal Cancer at ASCO GI 2022
January 18, 2022
From
Exelixis, Inc.
Via
Business Wire
Analyst Ratings For Exelixis
November 03, 2021
Over the past 3 months, 5 analysts have published their opinion on Exelixis (NASDAQ:
Via
Benzinga
Biotech Bloodbath Continues Despite Gene-Editing Deals For Pfizer, Bayer
January 10, 2022
Pfizer and Bayer inked deals with several companies in gene-editing.
Via
Investor's Business Daily
A Peek Into The Markets: US Stock Futures Edge Higher; Crude Oil Up 0.5%
January 10, 2022
Pre-open movers U.S. stock futures traded slightly higher in early pre-market trade after the three major averages recorded losses last week. Investors are awaiting earnings...
Via
Benzinga
Early Monday Report - More Moves Out Of China
January 09, 2022
Before it even turned Monday in the West, China insurers are feeling the heat.
Via
Talk Markets
Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Financial Guidance, and Outlines Key Priorities and Milestones for 2022
January 09, 2022
From
Exelixis, Inc.
Via
Business Wire
Post-Fed Thursday
January 06, 2022
Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today.
Via
Talk Markets
Exelixis and Iconic Therapeutics Amend Option and License Agreement for XB002, an Antibody-Drug Conjugate Targeting Tissue Factor
January 06, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-03 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Renal Cell Carcinoma
January 05, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis to Present at the Virtual 40th Annual J.P. Morgan Healthcare Conference on January 10, 2022
January 04, 2022
From
Exelixis, Inc.
Via
Business Wire
Exelixis Appoints Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer
January 04, 2022
From
Exelixis, Inc.
Via
Business Wire
7 of the Best Cheap Stocks Under $20 for 2022 to Buy Now
January 03, 2022
These cheap stocks are trading at highly attractive prices and have the potential to break through this year.
Via
InvestorPlace
The Daily Biotech Pulse: Novartis Snags Twin FDA Nods, Novavax Positive Vaccine News Continues, Arcutis Psoriasis Application Accepted For Review
December 23, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Novartis Receives FDA Nods For Arthritis Treatment And Cholesterol Drug...
Via
Benzinga
Exelixis Elects Jacqueline Wright to Its Board of Directors
December 17, 2021
From
Exelixis, Inc.
Via
Business Wire
Uncertain Times
December 15, 2021
The UK inflation rate last month was 5.1%, not a good omen.
Via
Talk Markets
Exelixis Announces Initiation of Phase 1b Trial Evaluating XL092 in Combination with Immuno-oncology Therapies in Patients with Advanced Solid Tumors
December 15, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Detailed Results from Phase 3 COSMIC-312 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer at ESMO Asia Virtual Oncology Week 2021
November 20, 2021
From
Exelixis, Inc.
Via
Business Wire
Exelixis Announces Enrollment Completion in Phase 3 CONTACT-01 Pivotal Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Previously Treated Metastatic Non-Small Cell Lung Cancer
November 09, 2021
From
Exelixis, Inc.
Via
Business Wire
3 No-Brainer Biotech Stocks to Buy in November
November 04, 2021
Here are three Motley Fool contributors' top picks.
Via
The Motley Fool
Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in November and December
November 03, 2021
From
Exelixis, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
November 03, 2021
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion...
Via
Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
November 03, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics...
Via
Benzinga
Topics
Retirement
Exposures
Pension
< Previous
1
2
...
8
9
10
11
12
13
14
15
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.